Calculus Capital Ltd. — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Inviziusinvizius.cominMay 2021
Invizius develops therapeutics targeting the complement system to treat kidney disease and other disorders driven by uncontrolled immune activation.
BiotechDeep TechHealthtechMedical DevicesGlasgow, GB
Dr Magnus Nicolsonin
Co-investorsCalculusMercia VenturesOld College CapitalScottish Enterprise
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.